Agenus Company Profile (NASDAQ:AGEN)

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AGEN
  • CUSIP: 00847G70
  • Web:
  • Market Cap: $521.36 million
  • Outstanding Shares: 99,118,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $3.88
  • 52 Week Range: $3.20 - $7.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $43.57 million
  • Price / Sales: 11.97
  • Book Value: $0.09 per share
  • Price / Book: 58.44
  • EBIDTA: ($85,440,000.00)
  • Net Margins: -257.79%
  • Return on Equity: -37,577.49%
  • Return on Assets: -57.26%
  • Debt-to-Equity Ratio: 15.07%
  • Current Ratio: 3.80%
  • Quick Ratio: 3.79%
  • Average Volume: 971,981 shs.
  • Beta: 2.03
  • Short Ratio: 9.82
Frequently Asked Questions for Agenus (NASDAQ:AGEN)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its earnings results on Thursday, May, 4th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The firm earned $26.96 million during the quarter, compared to analysts' expectations of $5.22 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 257.79%. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

4 equities research analysts have issued 1 year price targets for Agenus' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Agenus' stock price to reach $6.33 in the next year. View Analyst Ratings for Agenus.

What are analysts saying about Agenus stock?

Here are some recent quotes from research analysts about Agenus stock:

  • 1. According to Zacks Investment Research, "Agenus' collaboration agreements with players like Incyte and Merck not only validate its technology platforms but also provide the company with funds. In fact, it received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. We are encouraged by Agenus’ efforts in developing Prophage vaccine for glioblastoma multiforme. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates. However, with no approved product in its portfolio, Agenus is heavily dependent on collaborators for topline growth. Shares of the company have underperformed the Medical-Biomedical/Genetics industry year to date." (7/5/2017)
  • 2. Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)

Who are some of Agenus' key competitors?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

  • Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder
  • Christine M. Klaskin, Vice President - Finance
  • Karen Higgins Valentine, General Counsel, Chief Legal Officer
  • Ozer Baysal, Chief Commercial Officer, Head of HR
  • Jean-Marie Cuillerot M.D., Chief Medical Officer
  • Brian Corvese, Independent Director
  • Wadih Jordan, Independent Director
  • Shalini Sharp, Independent Director
  • Ulf Wiinberg, Independent Director
  • Timothy R. Wright, Independent Director

Who owns Agenus stock?

Agenus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.14%) and Quotient Investors LLC (0.05%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of Agenus stock can currently be purchased for approximately $5.26.

MarketBeat Community Rating for Agenus (NASDAQ AGEN)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Agenus (NASDAQ:AGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.33 (20.41% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/23/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $15.00N/AView Rating Details
12/31/2015Oppenheimer Holdings, Inc.Reiterated RatingPositive -> Outperform$14.00N/AView Rating Details
9/10/2015William BlairReiterated RatingBuyN/AView Rating Details
7/27/2015MLV & Co.Reiterated RatingBuy$9.00 -> $11.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Agenus (NASDAQ:AGEN)
Earnings by Quarter for Agenus (NASDAQ:AGEN)
Earnings History by Quarter for Agenus (NASDAQ AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017($0.38)N/AView Earnings Details
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agenus (NASDAQ:AGEN)
2017 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.33)($0.24)($0.29)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.34)($0.31)($0.33)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)
Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 42.61%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.00View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.00View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.00View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
DateHeadline logoZacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $6.49 Million - July 26 at 1:00 PM logoIs a Beat in Store for Agenus (AGEN) this Earnings Season? - July 24 at 1:40 PM logo Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share - July 24 at 12:36 PM logoIs a Beat in Store for Alexion (ALXN) this Earnings Season? - July 20 at 4:16 PM logouniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher - July 20 at 4:16 PM logoAgenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session - July 19 at 4:24 PM logoAgenus Inc. (NASDAQ:AGEN) Scheduled to Post Quarterly Earnings on Wednesday - July 19 at 9:00 AM logoAgenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9% - July 10 at 4:20 PM logoAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Buy" by Brokerages - July 10 at 11:14 AM logoAgenus Inc. (AGEN) Cut to "Strong Sell" at ValuEngine - July 8 at 10:52 PM logoAlexion Reportedly Being Investigated by HHS, Shares Slip - July 7 at 5:21 PM logoGeron Stock Up Almost 40% So Far This Year After '16 Decline - July 5 at 4:03 PM logoAgenus Inc. (AGEN) Rating Increased to Buy at Zacks Investment Research - July 5 at 2:06 PM logoIs the Options Market Predicting a Spike in Agenus (AGEN) Stock? - Nasdaq - July 3 at 3:31 PM logoBetter Buy: Agenus Inc. vs. Kite Pharma - Motley Fool - July 3 at 3:31 PM logoIs the Options Market Predicting a Spike in Agenus (AGEN) Stock? - July 3 at 3:31 PM logoGlioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research - July 3 at 6:22 AM logoBetter Buy: Agenus Inc. vs. Kite Pharma - July 2 at 8:11 AM logoThese Two Biotech Stocks Could Move On Near Term Vaccine Catalysts - June 30 at 3:40 PM logoZacks: Analysts Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $5.29 Million - June 30 at 2:31 PM logoFY2021 Earnings Forecast for Agenus Inc. (AGEN) Issued By William Blair - June 29 at 1:34 PM logo-$0.38 EPS Expected for Agenus Inc. (AGEN) This Quarter - June 28 at 8:28 AM logoQ2 2017 EPS Estimates for Agenus Inc. (AGEN) Increased by William Blair - June 28 at 7:36 AM logoAgenus Inc. (AGEN) Expected to Post FY2020 Earnings of ($1.17) Per Share - June 27 at 3:26 PM logoAgenus to Webcast Annual Meeting of Stockholders - PR Newswire (press release) - June 21 at 4:07 PM logoPositive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant - PR Newswire (press release) - June 21 at 4:07 PM logoAgenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : June 21, 2017 - June 21 at 4:07 PM logoAgenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session - June 21 at 4:07 PM logoAgenus to Webcast Annual Meeting of Stockholders - June 21 at 4:07 PM logoPositive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant - June 21 at 4:07 PM logoGSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting - June 21 at 4:07 PM logoAgenus (AGEN) Down 15.7% Since Earnings Report: Can It ... - Nasdaq - June 8 at 3:30 PM logoAgenus (AGEN) Down 15.7% Since Earnings Report: Can It Rebound? - June 8 at 3:30 PM logoAgenus' anti-CTLA-4 antibody shows strong safety and tolerability - PR Newswire (press release) - June 6 at 10:33 AM logoAgenus' anti-CTLA-4 antibody shows strong safety and tolerability - June 5 at 1:33 PM logo Brokerages Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $5.19 Million - June 4 at 9:50 AM logo-$0.39 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter - June 2 at 7:34 AM logoAgenus to Participate at Two Upcoming Conferences in New York ... - PR Newswire (press release) - June 1 at 3:33 PM logoAgenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences - June 1 at 3:33 PM logoNoteworthy Tuesday Option Activity: GOOG, PANW, AGEN - May 30 at 3:30 PM logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO ... - PR Newswire (press release) - May 22 at 3:24 PM logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting - May 22 at 3:24 PM logoETFs with exposure to Agenus, Inc. : May 22, 2017 - May 22 at 3:24 PM logoResearch Reports Initiation on Biotech Stocks -- Agenus, Athersys ... - PR Newswire (press release) - May 19 at 3:24 PM logoETFs with exposure to Agenus, Inc. : May 11, 2017 - May 11 at 8:48 PM logo$5.19 Million in Sales Expected for Agenus Inc (AGEN) This Quarter - May 10 at 9:16 AM logoAgenus, Inc. :AGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:23 PM logo Brokerages Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.31 Per Share - May 8 at 10:27 PM logoAgenus, Inc. – Value Analysis (NASDAQ:AGEN) : May 8, 2017 - May 8 at 8:47 PM logoAgenus Stock Bounces on Q1 Report, Update - May 5 at 8:25 PM



Agenus (AGEN) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff